Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 5/20 | 0.42 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.39 |
| ▸ | CDK9 | P50750 | 6/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5004837 | 0.93 | CCNT1 (0.40) | KITNAMPTEGFRCCNT1CDK9 | |
| SCHEMBL5004929 | 0.93 | CCNT1 (0.42) | KITEGFRERBB2CCNT1CDK9 | |
| SCHEMBL5004741 | 0.93 | CCNT1 (0.41) | KITNAMPTEGFRCCNT1CDK9 | |
| SCHEMBL5010289 | 0.93 | CCNT1 (0.41) | KITNAMPTEGFRCCNT1CDK9 | |
| SCHEMBL5001673 | 0.91 | NAMPT (0.42) | KITNAMPTEGFRBTKERBB2 | |
| SCHEMBL13994223 | 0.91 | CCNT1 (0.46) | BTKCCNT1CDK9 | |
| SCHEMBL5005376 | 0.90 | CCNT1 (0.41) | BTKCCNT1CDK9 | |
| SCHEMBL5005594 | 0.90 | KIT (0.43) | KITEGFRBTKCCNT1CDK9 | |
| SCHEMBL13994208 | 0.89 | CCNT1 (0.38) | KITEGFRBTKCCNT1CDK9 | |
| SCHEMBL13994186 | 0.89 | CCNT1 (0.52) | EGFRCCNT1CDK9IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | BMX, ERBB2, FRK | KIT 591/4885NAMPT 3067/4885EGFR 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.